Oncternal Therapeutics Inc.’s filing revealed that its Chief Scientific Officer Kaufmann Gunnar F. acquired Company’s shares for reported $1079.0 on Jun 14. In the deal valued at $0.36 per share,3,000 shares were bought. As a result of this transaction, Kaufmann Gunnar F. now holds 94,726 shares worth roughly $ 28417.8.
Then, Kaufmann Gunnar F. bought 25,000 shares, generating $8,745 in total proceeds. Upon buying the shares at $0.35, the Chief Scientific Officer now owns 91,726 shares.
Before that, BREITMEYER JAMES B bought 50,000 shares. Oncternal Therapeutics Inc. shares valued at $14,930 were divested by the Chief Executive Officer at a price of $0.30 per share. As a result of the transaction, BREITMEYER JAMES B now holds 196,544 shares, worth roughly $58963.2.
Oppenheimer initiated its Oncternal Therapeutics Inc. [ONCT] rating to an Outperform in a research note published on Friday, April 07, 2021; the price target was $14. PT values the company’s stock at a premium of 97.86 to its Friday closing price.
Price Performance Review of ONCT
On Friday, Oncternal Therapeutics Inc. [NASDAQ:ONCT] saw its stock jump 0.03% to $0.30. On the same session, the stock had its day’s lowest price of $0.2967, but rose to a high of $0.311. Over the last five days, the stock has lost -9.06%. Oncternal Therapeutics Inc. shares have fallen nearly -69.99% since the year began. Nevertheless, the stocks have fallen -73.21% over the past one year. While a 52-week high of $1.33 was reached on 01/18/23, a 52-week low of $0.26 was recorded on 04/10/23. SMA at 50 days reached $0.3655, while 200 days put it at $0.6434. A total of 0.26 million shares were traded, compared to the trading of 0.22 million shares in the previous session.
Levels Of Support And Resistance For ONCT Stock
The 24-hour chart illustrates a support level at 0.2942, which if violated will result in even more drops to 0.2883. On the upside, there is a resistance level at 0.3085. A further resistance level may holdings at 0.3169. The Relative Strength Index (RSI) on the 14-day chart is 40.70, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0192, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 91.56%. Stochastics %K at 9.34% indicates the stock is a buying.
How much short interest is there in Oncternal Therapeutics Inc.?
A steep rise in short interest was recorded in Oncternal Therapeutics Inc. stocks on Aug 14, 2023, dropping by -0.13 million shares to a total of 0.32 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 0.45 million shares. There was a decline of -39.81%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 0.59% of the overall stock float, the days-to-cover ratio (short ratio) fell to 1.36.
Oncternal Therapeutics Inc. [ONCT] – Who Are The Largest Shareholders?
In filings from The Vanguard Group, Inc., it is revealed that the company now owns 2,844,220 shares, or roughly 4.84% of the outstanding ONCT shares. In other words, the investor’s shares have fallen by -3,234 from its previous 13-F filing of 2847454.0. Additionally, Millennium Management LLC increased 9.98% of its stake after which the total value it holdings stand at $608,604, while BlackRock Fund Advisors reduced -12.42% of its stake to hold $0.29 million in the firm. At present, BIT Capital GmbH is holding 417,000 shares valued at $0.15 million. Geode Capital Management LLC owned 415,584 shares of the company at the time of its most recent 13F filing, worth $0.15 million.
According to FactSet, Oncternal Therapeutics Inc.’s share price will average $1.90 in the next year, based on opinions of analysts polled by the firm. This is up nearly 533.33 percent from its previous closing price of $0.30. Analysts expect Oncternal Therapeutics Inc. stock to reach the higher price of $2.50, while the lowest price estimate is $1.30. However, 5 analysts have rated ONCT stock as a Hold in their predictions for 2023.